Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + siplizumab + equine antithymocyte globulin + cyclophosphamide + tegoprubart
- Development stage
- Unknown
- Lead developer
- Eledon Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Rituxan + siplizumab + ATGAM + cyclophosphamide + tegoprubart (the Sip-Tego regimen) is an investigational multi-drug conditioning protocol used to induce donor-specific immunologic tolerance in recipients of combined kidney and bone marrow transplants. Developed by researchers at Massachusetts General Hospital, the regimen combines several immunosuppressive and immunomodulatory agents: rituximab (a CD20-targeting monoclonal antibody for B-cell depletion), siplizumab (an anti-CD2 monoclonal antibody that modulates T and NK cells), ATGAM (equine anti-thymocyte globulin for T-cell depletion), cyclophosphamide (an alkylating agent for lymphodepletion), and tegoprubart (a CD40L/CD154-blocking antibody to prevent costimulation). The primary goal of this regimen is to facilitate mixed hematopoietic chimerism, allowing the patient's immune system to coexist with the donor organ without the need for lifelong maintenance immunosuppression. It is currently being evaluated in a Phase 1 clinical trial for adult patients with end-stage renal disease (ESRD).
- Other names
- Rituxan + siplizumab + ATGAM + cyclophosphamide + tegoprubart
02
Targets
C1Q (Complement C1q)CD2 (T-cell Surface Antigen CD2)CD20 (B-lymphocyte antigen CD20)CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)CD4 (T lymphocyte surface antigen)CD40LG (CD40 ligand extracellular domain)CD8A (CD8 alpha/beta Coreceptor)DNAFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on rituximab + siplizumab + equine antithymocyte globulin + cyclophosphamide + tegoprubart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + siplizumab + equine antithymocyte globulin + cyclophosphamide + tegoprubart.